Invivyd Results and Recent Business Highlights

 

• Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise
• PEMGARDA product availability in the U.S. anticipated imminently
• PEMGARDA is the first authorized mAb from Invivyd’s INVYMAB™ platform approach designed to address the challenge of rapid viral evolution
• Leveraged INVYMAB platform approach to design VYD2311, the company’s next anticipated SARS-CoV-2 candidate
• Cash and cash equivalents of $200.6 million as of December 31, 2023
• In February 2024, the Company sold shares totaling $40.5 million in gross proceeds under its At-the-Market facility further strengthening its balance sheet ahead of PEMGARDA launch

https://www.globenewswire.com/news-release/2024/03/28/2853831/0/en/Invivyd-Reports-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights.html